Overview
MANE market data
Price History
MANE price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.00 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.59 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $32.00 – $131.24 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $4.6K.
Company news
Veradermics shares are trading higher after the company announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss.Benzinga · Jul 17, 2026, 5:52 PM
Veradermics Presents Data From Phase 2/3 Trial 302 Of VDPHL01 In Male Participants With Mid-To-Moderate Pattern Hair LossBenzinga · Jul 17, 2026, 11:32 AM
Citigroup Maintains Buy on Veradermics, Raises Price Target to $160Benzinga · Jul 16, 2026, 8:27 PM
Veradermics shares are trading higher after the company released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair loss. Also, Needham maintained its Buy rating on the stock and raised its price target from $136 to $164.Benzinga · Jul 15, 2026, 5:49 PM
Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 MonthsBenzinga · Jul 15, 2026, 5:47 PM
Needham Maintains Buy on Veradermics, Raises Price Target to $164Benzinga · Jul 15, 2026, 5:10 PM
PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On WednesdayBenzinga · Jul 15, 2026, 1:56 PM
8-K filing — Veradermics, Inc (MANE)SEC EDGAR · Jul 15, 2026, 12:54 PM
Veradermics’ VDPHL01 Phase 2 Trial Met Key Endpoints In Female Pattern Hair Loss, Showing Rapid Onset Of Hair Growth, 88.9%–90.0% Patient‑Reported Improvement At Month 6; Topline Phase 2/3 Study 306 Results Expected In H1 2027Benzinga · Jul 15, 2026, 11:10 AM
B. Riley Securities Initiates Coverage On Veradermics with Buy Rating, Announces Price Target of $170Benzinga · Jul 15, 2026, 10:27 AM